3 Promising Cancer Immunotherapies to Watch in 2018
Any way you look at it, immunotherapies -- also known as immuno-oncology (I-O) drugs -- are hot commodities. Two of the top three cancer drugs projected to be the biggest winners in the next five years are immunotherapies: Bristol-Myers Squibb's (NYSE: BMY) Opdivo and Merck's (NYSE: MRK) Keytruda. Together, those two combined are on track to generate revenue topping $8 billion this year.
Immunotherapies work by spurring the body's immune system to fight cancer. The approach has gained such incredible traction in the research community that there are now over 2,000 immunotherapies in clinical-stage development or on the market. Out of that vast number, I think there are three especially promising cancer immunotherapies to watch in 2018.
Image source: Getty Images.
Source: Fool.com
Incyte Corp. Aktie
Klare Kaufstimmung für Incyte Corp.: Viel mehr Buy- als Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 114 € für Incyte Corp. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 104.0 € hin.
